Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

@article{Dormandy2005SecondaryPO,
  title={Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.},
  author={John A. Dormandy and Bernard H Charbonnel and David J A Eckland and Erland Erdmann and M. Massi-Benedetti and Ian K Moules and Allan M. Skene and Moe Hsiang Tan and P. Lefebvre and Gordon D. Murray and Eberhard Standl and Robert G. Wilcox and Lars Wilhelmsen and John Betteridge and K{\aa}re I Birkeland and Alain Golay and R. Heine and L{\'a}szl{\'o} Kor{\'a}nyi and Markku Laakso and Mari{\'a}n Mok{\'a}ň and Antanas Norkus and Valdis Pīrāgs and Toomas Podar and Andr{\'e} Scheen and Werner Alfred Scherbaum and Guntram Schernthaner and Otto Schmitz and Jan V Skrha and Ulf Smith and Jan Taton},
  journal={Lancet},
  year={2005},
  volume={366 9493},
  pages={1279-89}
}
BACKGROUND Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes. METHODS We did a prospective, randomised controlled trial in 5238 patients with type 2… CONTINUE READING
Highly Influential
This paper has highly influenced 64 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 13 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 1,351 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Tight glucose control lowers CVD by about 50 percent in diabetes

  • MN Feinglos, MA Bethel
  • NIH News
  • 2005

Drug therapy : thiazolidinediones

  • A Pf̊tzner, N Marx, G L̊bben
  • N Engl J Med
  • 2004

Similar Papers

Loading similar papers…